Abstract:Chronic hepatitis C virus (HCV) infection exerts its main effects on the liver, promoting hepatic inflammation and fibrosis and increasing the risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma [1]. However, chronic HCV infection also affects organ systems outside of the liver and can contribute to the development of a variety of extrahepatic diseases, most notably atherosclerosis, metabolic alterations (eg, insulin resistance, diabetes mellitus, hepatic steatosis), renal disease (eg, proteinuria, membranoproliferative glomerulonephritis), bone disease (eg, arthralgias, osteoporosis, fractures), neuropsychiatric manifestations (eg, fatigue, cognitive impairment), B-cell non-Hodgkin’s lymphoma, cutaneous disorders (eg, lichen planus, porphyria cutanea tarda), and autoimmune and immune-mediated conditions (eg, mixed cryoglobulinemia, thyroid disease, sicca syndrome) [2, 3]. Some studies have suggested that the incidence of these diseases might be higher for human immunodeficiency virus (HIV)/HCV–coinfected individuals than for those with HCV alone [4, 5]. Regardless of HIV status, HCV-related extrahepatic conditions contribute to morbidity and could increase the risk of nonliver-related mortality [6–9]. The mechanisms for the extrahepatic comorbidities associated with chronic HCV infection are incompletely understood but are likely multifactorial. HCV replication in extrahepatic cells, interactions between HCV proteins and intracellular signaling pathways, HCVinduced stimulation of B-lymphocytes, and immune activation leading to chronic inflammation have all been hypothesized to play a role in the development of these conditions [2, 3]. Lifestyle factors, such as drug and alcohol abuse, smoking, and poor nutrition, may also be important contributors to the development of HCVrelated extrahepatic diseases. There is evidence that successful eradication of chronic HCV infection with interferon-based therapy can ameliorate some extrahepatic complications. Achieving cure of chronic HCV has been associated with improvements in insulin resistance [10–12], reduced risk of diabetes [13], decreased incidence of stroke [14] and lymphoma [15], improvement in neurocognitive function [16], reduction in fatigue [17], and resolution of mixed cryoglobulinemia [18]. These studies were primarily conducted among HIV-uninfected patients, and it remains unclear if HIV differentially affects the impact of cured HCV on specific extrahepatic conditions. Successful treatment of chronic HCV also has been shown to reduce non-liver– related mortality. One cohort study of 530 chronic HCV-infected patients with advanced hepatic fibrosis or cirrhosis found that eradication of chronic HCV with interferon-based treatment significantly reduced rates of all-cause mortality [7], but this study excluded individuals with HIV coinfection. However, a separate cohort study of 1599 HIV/HCV–coinfected patients found that cure of chronic HCV with interferon plus ribavirin was associated with reductions in non-liver– related deaths as well as decreased HIV progression [8]. All-oral direct-acting antiviral (DAA) agents for the treatment of chronic HCV are now available and result in high (≥94%) rates of cure, regardless of HIV status, with minimal adverse effects [19– 22]. Because of their high costs, access to these drugs has been limited in many settings, often only restricted to patients with advanced liver fibrosis or cirrhosis [23–26]. However, if successful treatment of chronic HCV with DAA regimens is shown to improve HCV-related extrahepatic diseases and can reduce nonhepatic morbidity and mortality, including among HIV/HCV–coinfected individuals, then extrahepatic manifestations of chronic HCV may become a major E D I T O R I A L C O M M E N T A R Y

CD4+ T‐cell recovery in HIV/hepatitis C co‐infected patients following successful hepatitis C treatment

[Highly Active Antiretroviral Therapy on Liver Function in HIV-positive Children with HBV/HCV Co-Infection].

In HIV-Infected Immunological Non-Responders, Hepatitis C Virus Eradication Contributes to Incomplete Normalization of Systemic Inflammation Indexes, but Does Not Lead to Rapid CD4+ T-Cell Count Recovery

Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study

Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy

The Factors Related To Cd4+T-Cell Recovery And Viral Suppression In Patients Who Have Low Cd4+T Cell Counts At The Initiation Of Haart: A Retrospective Study Of The National Hiv Treatment Sub-Database Of Zhejiang Province, China, 2014

Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis

Antiretroviral Therapy, Interferon Sensitivity, and Virologic Setpoint in Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Patients

Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy

Changes in Hepatic Steatosis Before and After Direct-Acting Antiviral Treatment in People With HIV and Hepatitis C Coinfection

Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care

Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis

A retrospective follow-up study of hepatitis C virus related cirrhosis treated with direct-acting antiviral agent

Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C Shows Liver Fibrosis Regression on Three Noninvasive Tests: A Puerto Rican Cohort

HIV Co-Infection Accelerates Decay of Humoral Responses in Spontaneous Resolvers of HCV Infection.

DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV

More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections.